Sequencing of the ~60% of patient tumour cells with PIK3CA-E545K mutation revealed that in at least 80% of the cases, the mutation was heterozygous i.e. patient tumour cells expressed both PIK3CA-WT and PIK3CA-E545K [27]. The gene discussed is PIK3CA; the disease is neoplasm.